Soligenix, inc. (SNGX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Contract revenue

845

568

946

1,060

639

756

1,064

1,367

777

-

1,395

990

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant revenue

79

117

307

484

505

258

316

357

342

-

426

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

1,330

1,698

2,959

3,160

2,630

2,972

3,874

1,082

712

1,792

2,194

892

666

565

0

0

0

-

-

-

-

-

-

-

-

-

-

License revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

-

-

0

-

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-

0

5

17

103

134

592

526

244

813

312

632

900

802

931

762

647

653

795

405

808

860

-

Total revenues

924

685

1,254

1,544

1,144

1,014

1,381

1,725

1,119

1,288

1,822

990

1,330

-

2,959

-

-

2,972

3,879

1,099

816

1,926

2,787

1,418

910

1,379

312

632

900

-

-

-

-

-

5,795

-

-

860

444

Cost of revenues

829

587

965

1,086

927

887

1,237

1,493

978

1,071

1,474

677

1,087

1,228

2,630

2,342

2,232

2,487

3,050

816

527

1,540

2,109

1,034

628

1,026

245

527

743

658

761

616

556

549

655

349

554

779

349

Gross profit

95

98

289

458

216

126

144

231

140

217

347

313

243

469

329

817

398

485

828

283

288

385

678

383

281

352

66

104

156

144

169

146

90

103

5,140

56

253

81

95

Operating expenses:
Research and development

2,700

2,359

2,266

1,853

1,642

2,382

1,394

1,170

1,803

1,900

605

1,783

1,217

862

1,177

827

1,428

1,668

1,259

1,442

1,029

-2,246

5,089

1,213

1,030

957

1,216

2,140

756

860

371

500

876

1,043

2,342

1,513

1,372

1,276

1,070

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,089

-

-

-

1,216

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,000

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

868

1,048

789

769

874

901

667

650

731

886

711

846

764

902

650

999

875

1,064

839

874

817

966

730

866

840

846

710

719

487

791

558

627

655

567

595

475

604

543

544

Research and development expense - milestone

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation  research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39

Stock-based compensation  general and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

Total operating expenses

8,568

3,407

3,056

2,623

2,516

3,283

2,062

1,821

2,534

2,786

1,317

2,630

1,981

1,764

1,828

1,827

2,304

2,732

2,098

2,317

1,847

2,719

5,819

2,079

1,871

1,804

1,927

2,860

1,244

1,651

930

1,128

1,531

1,611

2,937

1,989

1,976

1,819

1,675

Loss from operations

-8,473

-3,309

-2,766

-2,164

-2,300

-3,157

-1,918

-1,589

-2,394

-2,569

-969

-2,316

-1,738

-1,295

-1,498

-1,009

-1,905

-2,247

-1,269

-2,034

-1,558

-2,334

-5,141

-1,695

-1,589

-1,452

-1,860

-2,755

-1,087

-1,507

-760

-981

-1,440

-1,508

2,203

-1,932

-1,722

-1,738

-1,580

Other income:
Foreign currency transaction (loss)/gain

-23

-

-

-

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-432

176

-525

-760

294

-4,047

1,943

3,011

-3,639

-791

-746

1,742

-

4,699

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

13

6

5

4

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

390

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-3

-5

-3

0

0

0

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

21

-

-

-

44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

1

2

2

1

1

2

4

2

Research and development incentives

-56

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-649

0

-

0

0

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Other income, net

-

-

45

41

-

-

56

32

16

-

-

-

-

435

-174

917

756

-299

4,044

-1,942

-3,011

-

-

747

-1,741

-

-

-649

0

-

-

-

-

-

-

-

-

-

-

Net loss before income taxes

-8,418

-2,871

-2,720

-2,123

-2,250

-3,104

-1,861

-1,556

-2,377

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-836

0

0

0

-610

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-7,581

-2,871

-2,720

-2,123

-1,639

-3,104

-1,861

-1,556

-2,377

-2,138

-963

-2,311

-1,733

-329

-1,673

-92

-1,149

-2,058

2,774

-3,977

-4,569

1,922

-4,349

-948

-3,331

993

-6,559

-3,405

-1,087

-985

-758

-979

-1,438

-

-

-

-

-

-

Basic net loss per share

-

-

-

-

-

-

-

-

-

-

-0.17

-0.41

-0.32

-0.04

-0.49

-0.03

-0.37

-2.31

1.05

-1.55

-0.19

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-0.17

-0.41

-0.32

-0.07

-0.49

-0.19

-0.59

-0.81

-0.45

-1.55

-0.19

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

-

5,757

5,601

5,472

4,188

3,432

3,176

3,127

-19,200

2,648

2,572

24,405

-

20,671

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

-

5,757

5,601

5,472

4,368

3,432

3,273

3,260

-19,381

2,829

2,572

24,405

-

20,671

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,204

-1,931

-1,720

-1,733

-1,577

Basic and diluted net loss per share

-0.32

-0.13

-0.14

-0.12

-0.09

-0.12

-0.11

-0.18

-0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.05

-0.17

-

-

-0.28

-0.10

-0.08

-0.07

-0.09

-0.13

-0.08

0.20

-0.18

-0.16

-0.01

-0.01

Basic and diluted weighted average common shares outstanding

23,404

20,895

20,094

18,436

18,078

17,740

17,495

8,742

8,734

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19,949

19,739

-

-

12,259

11,180

11,163

11,138

11,124

11,119

-

11,013

10,899

-

-

-

Basic and diluted weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,842

215,869

190,751